Evidence map›Paper›PMID 41417445›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Global perspective on implementing ultra-hypofractionated radiation therapy in breast cancer: a survey-based analysis.

Tinatin Alaverdashvili, Angel Montero, Philip Poortmans

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tinatin AlaverdashviliDepartment of Radiation Oncology, Todua Clinic, 13 Tevdore Mgvdeli St., 0112, Tbilisi, Georgia. tinatinalaverdashvili@gmail.com.ORCID http://orcid.org/0009-0002-4299-6339
Angel MonteroDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Philip PoortmansDepartment of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to investigate global practice patterns, barriers, and physician perspectives on implementing ultra-hypofractionated radiation therapy (UHF-RT) in breast cancer treatment. MATERIALS AND

methodsA 19-question online survey, distributed to radiation oncologists worldwide between February and August 2025, assessed UHF adoption, clinical use, barriers, training, and outlook. Chi-square tests compared adoption by institutional type, economic context, and physician experience (p < 0.05).

results89 responses from 24 countries were analyzed. Moderate hypofractionation (MHF) predominated (70.8%), followed by UHF (20.2%). Overall, 80.9% had applied UHF, mainly for breast-only cases. Reported barriers included lack of clinical guidelines (49.2%), insufficient training (20.3%), equipment limitations (18.6%), and reimbursement issues (16.9%). No significant differences in adoption were found, though trends showed higher use in academic centers and high-income countries.

conclusionsUHF is increasingly adopted worldwide, yet MHF remains predominant. Standardizing education, infrastructure, and reimbursement policies could support wider global use.

Indexed as

Breast NeoplasmsPractice Patterns, Physicians'Radiation Dose HypofractionationRadiation OncologistsFemaleHumansRadiation OncologySurveys and QuestionnairesBreast cancerPractice patternsRadiation therapySurveyUltra-hypofractionation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.